Moreover, GSDMB gene is frequently co-amplified with ERBB2/HER2 oncogene in breast and gastro-esophageal carcinomas (Saeki et al., 2009; Hergueta-Redondo et al., 2016), and in HER2+ breast cancers GSDMB upregulation promotes tumor aggressiveness and resistance to anti-HER2 therapies (Hergueta-Redondo et al., 2016). The gene discussed is ERBB2; the disease is breast carcinoma.